We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dyax and Bayer Schering Enter into a Collaboration Agreement for Discovery of Therapeutic Antibodies
News

Dyax and Bayer Schering Enter into a Collaboration Agreement for Discovery of Therapeutic Antibodies

Dyax and Bayer Schering Enter into a Collaboration Agreement for Discovery of Therapeutic Antibodies
News

Dyax and Bayer Schering Enter into a Collaboration Agreement for Discovery of Therapeutic Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dyax and Bayer Schering Enter into a Collaboration Agreement for Discovery of Therapeutic Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dyax Corp. has announced that they have entered into an agreement with Bayer Schering Pharma AG for the discovery of therapeutic antibodies.

Under the terms of this agreement, Dyax will identify therapeutic antibodies for two targets provided by Bayer Schering Pharma. Furthermore, these research activities may be expanded to allow Dyax to work on additional targets and/or allow Bayer Schering Pharma to exercise an option for an antibody library license.

Dyax will receive clinical milestone payments and royalties on net sales that may result from Bayer Schering Pharma’s development and commercialization of any antibodies discovered through the collaboration.

The agreement also provides Bayer Schering Pharma with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’s technology. Financial terms were not disclosed.

“Dyax consistently generates new therapeutic antibody technology collaborations and has developed into one of the leaders in the industry for antibody drug discovery,” commented Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax.

“We are excited about the growing value of our Licensing and Funded Research Program, and look forward to building on its success in the future.”

Advertisement